Recombinant conglutinin and producing method thereof
CA 2229739 C · Owner: Fuso Pharmaceutical Industries, Ltd. · Inventors: Wakamiya, Nobutaka
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A recombinant conglutinin containing a collagen region comprising six amino acid residues containing two amino acid sequences Gly-Xaa-Xaa (SEQ ID NO:3 Xaa representing a protein-constituting amino acid residue) a neck region of , natural conglutinin and a sugar-chain recognition region of natural conglutinin, having an antiviral activity (neutralizing activity) and being , expected to be applicable for medicinal uses.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 2, 1995 and granted January 14, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 2, 2015.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 2, 2017.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.